A nanotech formulation may have saved one of the most promising broad-spectrum antiangiogenesis cancer therapies from being side-tracked due to neurotoxic side effects.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.